Summary
The California Supreme Court held that a drug manufacturer owes no duty of care when deciding whether and when to develop and bring to market an allegedly safer alternative to a product that is not defective. The decision, authored by Justice Groban over a dissent, cuts off a fast-growing theory that would have let plaintiffs sue manufacturers for injuries caused by non-defective products.
Every company that makes a product makes bets: what to build next, how fast to develop it, when to launch. Plaintiffs’ lawyers found a way to turn those bets into a lawsuit. The theory was simple. Don’t argue the product you sold was defective. Argue that you should have released a safer alternative sooner, and that the delay is what hurt the customer. For a few years, California courts let that theory survive. But on August 3, the California Supreme Court shut it down.
The case is Gilead Tenofovir Cases (Cal. Supreme Ct., Aug. 3, 2026), and while the facts are about HIV medication, the principle reaches every manufacturer that has ever kept one product on the shelf while working on the next.
Two Drugs and a Fifteen-Year Gap
Gilead makes tenofovir-based HIV treatments. Its first, TDF, won FDA approval in October 2001 and became a cornerstone of therapies that save millions of lives worldwide each year. (Before these drugs, HIV carried a 95 percent fatality rate.) One month after that approval, Gilead filed to begin human testing of a second compound, TAF, as a potential backup. A small early trial, fourteen days and thirty subjects, suggested TAF could match TDF’s antiviral effect at a much lower dose, which plaintiffs say meant less risk of kidney, bone, and tooth damage. In 2004, Gilead announced it was shelving TAF. It resumed development in 2010, ran its first large-scale clinical trial in 2013, and won FDA approval in November 2015, ahead of the 2017 expiration of its TDF patent.
The plaintiffs took TDF and allege they suffered serious injuries. Here is the key move. They concede TDF was not defective and don’t say Gilead should have pulled it. They say Gilead should have brought TAF to market years earlier, that they would have switched, and that the delay cost them a safer option. They also concede the data Gilead had in 2004 was not enough to get TAF approved.
Why the Court Refused to Require a Safer Alternative
The plaintiffs built their claim on negligence, the failure to use reasonable care, and on Civil Code section 1714, which sets a default rule that everyone must act with reasonable care to avoid harming others. The trial court let the negligence claim proceed. The Court of Appeal agreed that a manufacturer’s duty of care, its legal obligation to act reasonably toward others, could extend beyond simply not selling a defective product.
The Supreme Court reversed. It signaled doubts about whether a manufacturer can ever be liable in negligence for a nondefective product. Still, it did not have to resolve that larger question. Even assuming such a duty could exist, the Court held that the Rowland factors, the considerations California courts weigh when deciding whether to carve out an exception to the default duty of care, compel an exception here.
The reasoning is practical. A manufacturer cannot reliably know during early testing that a drug in development is safer, so it cannot foresee that any delay will harm users of the existing product. The link between a development decision and a later injury is attenuated, running through a chain of uncertain science and choices by regulators, doctors, and patients. And imposing the duty would backfire. It would invite hindsight second-guessing of complex research decisions, and it could push companies to stop investigating backup products, since an early hint of a safety improvement could later be turned into a lawsuit.
What This Means for Manufacturers and In-House Counsel
The holding is written for drug makers, but the logic travels. A manufacturer’s duty stays anchored to the product it actually sold and whether that product was defective. Your internal decisions about what to develop, how to prioritize research, and when to launch are not a separate source of tort liability just because a plaintiff can later point to something better in your pipeline.
Two things follow. First, if you sell a product that is not defective, a “you should have built a safer one faster” claim now runs straight into Gilead. Second, the Court’s willingness to use Rowland to rein in an expanding duty is worth remembering whenever a plaintiff tries to stretch ordinary negligence into new territory.
Bottom Line
Innovation involves timing, and timing involves judgment calls made under uncertainty. After Gilead, those judgment calls are far harder to convert into a negligence case in California, at least where the product you sold was not defective. If your company makes anything, read it before your next product-liability threat letter arrives. Horst Legal Counsel advises manufacturers, product companies, and in-house teams on liability exposure, litigation strategy, and risk management. If you want to talk through how Gilead affects your product line or a pending claim, we’re glad to help. Contact us here